Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
DAY 12-15
Liposomal Amphotericin B initiated
Liposomal Amphotericin B was chosen to help treat Abdullah's Candida infection, because it demonstrates:
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Ready to take on Abdullahِ's Candida infection10,13,14
Liposomal Amphotericin B shows in vitro
fungicidalactivity against Candida species,
including C. albicans and C. glabrata.14
fungicidalactivity against Candida species,
including C. albicans and C. glabrata.14
Very common adverse events associated with
Liposomal Amphotericin Btreatment include
rigors, pyrexia, hypokalaemia, nausea and
vomiting.13
Liposomal Amphotericin Btreatment include
rigors, pyrexia, hypokalaemia, nausea and
vomiting.13
Liposomal Amphotericin B demonstrates improved
tissue penetration with sustained drug levels and
activity in key target tissues, including the brain,
lungs, kidneys, liver and spleen, vs. conventional
amphotericin B.15
tissue penetration with sustained drug levels and
activity in key target tissues, including the brain,
lungs, kidneys, liver and spleen, vs. conventional
amphotericin B.15
*Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 16-20
Fever improved
Fungicidal activity against a variety of
Candida species14
Candida species14
Deep tissue penetration15
A well-established tolerability
and safety profile*13
and safety profile*13
